{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T22:35:52Z","timestamp":1776378952262,"version":"3.51.2"},"reference-count":23,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2023,12,1]]},"DOI":"10.18632\/oncotarget.28538","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T14:16:39Z","timestamp":1701440199000},"page":"949-956","source":"Crossref","is-referenced-by-count":1,"title":["Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin"],"prefix":"10.18632","volume":"14","author":[{"given":"Carsten","family":"Springer","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, St\u00e4dtisches Klinikum Braunschweig, Braunschweig, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Krauter","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, St\u00e4dtisches Klinikum Braunschweig, Braunschweig, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Trummer","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, St\u00e4dtisches Klinikum Braunschweig, Braunschweig, Germany"},{"name":"Department of Hematology, Oncology and Palliative Care, Heidekreis-Klinikum, Walsrode, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"5575","DOI":"10.3390\/cancers14225575","article-title":"Extracellular Vesicles in Multiple Myeloma-Cracking the Code to a Better Understanding of the Disease","volume":"1","author":"Pu\u0142a","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.3390\/cells10113185","article-title":"Role of Extracellular Vesicle-Based Cell-to-Cell Communication in Multiple Myeloma Progression","volume":"1","author":"Frassanito","year":"2021","journal-title":"Cells"},{"key":"3","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41408-021-00592-3","article-title":"\u201cReal-life\u201d data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience","volume":"1","author":"Hayman","year":"2021","journal-title":"Blood Cancer J"},{"key":"4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/bjh.18479","article-title":"Real-world experience with belantamab mafodotin therapy for relapsed\/refractory multiple myeloma: A multicentre retrospective study","volume":"20","author":"Horowitz","year":"2023","journal-title":"Br J Haematol"},{"key":"5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40487-022-00212-5","article-title":"Real-World Outcomes of Belantamab Mafodotin for Relapsed\/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)","volume":"1","author":"Bocanegra","year":"2023","journal-title":"Oncol Ther"},{"key":"6","doi-asserted-by":"publisher","first-page":"1026251","DOI":"10.3389\/fonc.2022.1026251","article-title":"Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience","volume":"1","author":"Gaeta","year":"2022","journal-title":"Front Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"8007","DOI":"10.1200\/JCO.2023.41.16_suppl.8007","article-title":"A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): DREAMM-3","volume":"4","author":"He","year":"2023","journal-title":"J Clin Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.leukres.2019.04.008","article-title":"Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells","volume":"8","author":"Zhou","year":"2019","journal-title":"Leuk Res"},{"key":"9","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"13","author":"Liu","year":"2019","journal-title":"Blood"},{"key":"10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"15","author":"Waterman","year":"2012","journal-title":"Br J Haematol"},{"key":"11","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients","volume":"10","author":"Swift","year":"2017","journal-title":"Haematologica"},{"key":"12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jaip.2019.08.012","article-title":"Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies","volume":"8","author":"Cunningham-Rundles","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"13","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium","volume":"4","author":"Atrash","year":"2023","journal-title":"J Clin Oncol"},{"key":"14","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJMoa2210140","article-title":"Nirogacestat, a \u03b3-Secretase Inhibitor for Desmoid Tumors","volume":"38","author":"D\u2019Amato","year":"2023","journal-title":"N Engl J Med"},{"key":"15","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/35070019","article-title":"Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing","volume":"3","author":"Br\u00e9ard","year":"2001","journal-title":"Nat Cell Biol"},{"key":"16","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"12","author":"Christie","year":"2014","journal-title":"Blood"},{"key":"17","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.3389\/fimmu.2018.01799","article-title":"Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E","volume":"9","author":"Ju","year":"2018","journal-title":"Front Immunol"},{"key":"18","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1159\/000479398","article-title":"Triggering of Eryptosis, the Suicidal Erythrocyte Death by Mammalian Target of Rapamycin (mTOR) inhibitor Temsirolimus","volume":"4","author":"Lang","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3390\/cells11030503","article-title":"Eryptosis: Programmed Death of Nucleus-Free, Iron-Filled Blood Cells","volume":"1","author":"Wieder","year":"2022","journal-title":"Cells"},{"key":"20","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3324\/haematol.2009.008938","article-title":"Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease","volume":"9","author":"Biemond","year":"2009","journal-title":"Haematologica"},{"key":"21","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study","volume":"9","author":"Opalinska","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"22","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1097\/TP.0000000000000881","article-title":"Epithelial and Erythrocyte Microvesicles From Bronchoalveolar Lavage Fluid Are Elevated and Associated With Outcome in Chronic Lung Allograft Dysfunction","volume":"9","author":"Trummer","year":"2015","journal-title":"Transplantation"},{"key":"23","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"1","author":"Boccadoro","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T14:16:45Z","timestamp":1701440205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,1]]}},"alternative-id":["28538"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28538","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}